Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

13 Mar 20264 min read0 viewsINTERVENTIONAL Trial

GIST

RECRUITING · INTERVENTIONAL · TREATMENT study · Chronic Lymphocytic Leukemia · Phase 2 · Enrollment 33 · Sponsor: City of Hope Medical Center

Clinical Editorial

Summary

ClinicalTrials.gov published a clinical update in Oncology on 13 Mar 2026. The item focuses on Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial. Open the detail page to review the full original feed content.